Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Redox Biology|November 6, 2025
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancerGayle S Jameson, S Danielle LeGrand, Michael S Gordon, et al.
Journal of Affective Disorders|June 16, 2000
Evaluating the parent-of-origin effect in bipolar affective disorder. Is a more penetrant subtype transmitted paternally?J R Kornberg, J L Brown, A D Sadovnick, et al.
Circulation Research|July 14, 2023
Loss of the Atrial Fibrillation-Related Gene, Zfhx3, Results in Atrial Dilation and ArrhythmiasHeather S Jameson, Alan Hanley, Matthew C Hill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsGayle S Jameson, John T Hamm, Glen J Weiss, et al.
Breast Cancer Research and Treatment|September 12, 2014
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancerGayle S Jameson, Emanuel F Petricoin, Jasgit Sachdev, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1979
Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary reportG Gahrton, M Björkholm, G Brenning, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Circulation. Cardiovascular Genetics|October 5, 2017
Diminished PRRX1 Expression Is Associated With Increased Risk of Atrial Fibrillation and Shortening of the Cardiac Action PotentialNathan R Tucker, Elena V Dolmatova, Honghuang Lin, et al.
The Oncologist|June 10, 2026
A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancerAlexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, et al.
Oncotarget|June 12, 2020
An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinomaKatherine M Bever, Erkut H Borazanci, Elizabeth A Thompson, et al.
Pageof 16